L. Gazzard

发表

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety.

Xianrui Zhao, Ignacio Aliagas, Ronen Marmorstein, 2015, ACS medicinal chemistry letters.

Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors.

Benjamin D. Sellers, Rohan V Mendonca, Sanjeev Kumar, 2020, ACS medicinal chemistry letters.

Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.

R. Scheller, S. Scales, Cary D. Austin, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Rhodium promoted isomerisation of allylic alkoxides: a new method for enolate anion formation

W. Motherwell, D. Sandham, L. Gazzard, 1999 .

Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).

Zhaoyang Wen, Brigitte Maurer, Vickie Tsui, 2012, Journal of medicinal chemistry.

Preparation of 1-fluoroglycosides from 1-arylthio and 1-arylselenoglycosides using 4-methyl(difluoroiodo)benzene

S. Caddick, W. Motherwell, L. Gazzard, 1996 .

Synthesis of the Kopsia alkaloids (±)-pauciflorine B, (±)-lahadinine B, (±)-kopsidasine, (±)-kopsidasine-N-oxide, (±)-kopsijasminilam and (±)-11-methoxykopsilongine

V. Lynch, L. Gazzard, P. Magnus, 2002 .

Development of an Expedient Process for the Multi-Kilogram Synthesis of Chk1 Inhibitor GDC-0425

M. Reynolds, L. Gazzard, A. Deese, 2015 .

Studies on the synthesis of the indole alkaloids pauciflorine A and B

V. Lynch, L. Gazzard, P. Magnus, 1999 .

Studies on the Synthesis of the Indole Alkaloids Pauciflorine A and B.

V. Lynch, L. Gazzard, P. Magnus, 1999 .

Identifying transcriptional programs underlying cancer drug response with TraCe-seq

Z. Modrušan, Matthew T. Chang, S. Malek, 2021, Nature Biotechnology.

Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation.

Ivana Yen, S. Malek, F. Shanahan, 2023, Cell chemical biology.

Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.

I. Aliagas, K. Hoeflich, Weiru Wang, 2016, Journal of medicinal chemistry.

Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900

Ivana Yen, S. Malek, T. O'Brien, 2013, Molecular Cancer Therapeutics.

Small Molecule Therapeutics Combination Drug Scheduling De fi nes a " Window of Opportunity " for Chemopotentiation of Gemcitabine by an Orally Bioavailable , Selective ChK 1 Inhibitor , GNE-900

Ivana Yen, S. Malek, T. O'Brien, 2013 .

Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres.

C. Ly, W. Fairbrother, V. Tsui, 2010, Bioorganic & medicinal chemistry letters.

Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).

Benjamin D. Sellers, Rohan V Mendonca, G. Hatzivassiliou, 2018, ACS medicinal chemistry letters.

Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors

Melinda M. Mulvihill, H. Koeppen, Y. Franke, 2022, Nature Biotechnology.

Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1.

M. Gill, G. Médard, E. Gancia, 2015, Journal of medicinal chemistry.

Identifying transcriptional programs underlying cancer drug response with TraCe-seq

Z. Modrušan, Matthew T. Chang, S. Malek, 2021, Nature Biotechnology.

Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).

Hoai An Le Thi, E. Gancia, BinQing Wei, 2021, ACS medicinal chemistry letters.

Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1.

Ivana Yen, S. Sideris, S. Malek, 2014, Bioorganic & medicinal chemistry letters.